Kane Biotech's Antibiofilm Technologies Published in Two New Scientific Books
WINNIPEG, MANITOBA -- (MARKET WIRE) -- 02/23/10 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company's Research and Development (R&D) team has made contributions to two new scientific books. At the invitation of the publishers, Humana Press and Nova Science Publishers, respectively, Kane Biotech's team has authored two book chapters reviewing their biofilm research methodology and the antibiofilm-antimicrobial technology development strategy for bacterial infection control.
The contributions included a chapter in the book "Antimicrobial Peptides: Methods and Protocols (Eds. Andrea Giuliani & Andrea C. Rinaldi, Chapter 24, 2010)" entitled "Antimicrobial and Antibiofilm Activity of Quorum Sensing Peptides and Peptide Analogues against Oral Biofilm Bacteria" by K. LoVetri and S. Madhyastha. The chapter provides a review of the assay methods used by Kane Biotech to test the inhibitory effects of quorum sensing peptides and their analogues on the growth and biofilm formation of oral bacteria.
Additionally, the Company's R&D team contributed a chapter to the book "Biofouling: Types, Impact and Anti-Fouling (Eds. Jun Chan & Shing Wong, Chapter 4, 2010) entitled "Biofouling and Anti-fouling of Medical Devices" by K. LoVetri, P.V. Gawande, N. Yakandawala and S. Madhyastha. The chapter provides a review of Kane Biotech's research related to developing antibiofilm-antimicrobial technologies.
"The invited contribution of chapters to these new books on biofilm-related research and solutions is recognition of Kane Biotech's contributions to applied biofilm research and technology development," stated Dr. Sri Madhyastha, VP-Research & Chief Scientific Officer of Kane Biotech. "We are proud of our recognized capability to develop antibiofilm-antimicrobial technologies based on sound science."
"The chapters in these books contribute to the scientific awareness as well as knowledge of biofilm research and solutions," stated Gord Froehlich, President and CEO of Kane Biotech. "It also acknowledges that Kane Biotech is a key player in developing antibiofilm-antimicrobial technologies for medical and industrial applications."
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Kane Biotech Inc. Gord Froehlich President & Chief Executive Officer 204-477-7592 204-453-1314 (FAX) info@kanebiotech.com www.kanebiotech.com
Released February 23, 2010